Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy

The company is employing AI to design lipid nanoparticles (LNPs) with the goal of creating programmable drug treatments. “Mana.bio’s integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines,” company co-founder and CEO Yogev Debbi said in a statement.

Read the full article here